FDA grants Roche’s Avastin full approval for most aggressive form of brain cancer
Roche announced the FDA has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therap. Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program. December 06, 2017